Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir

Pharmaceutical Research

Volumn 23, Issue 8, 2006, Pages 1750-1755

  Snedecor, Sonya J ^a,d   Sullivan, Sean M ^a,b   Ho, Rodney J Y ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b Let There Be Hope Medical Research Institute   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PHARMERIT INTERNATIONAL   (United States)

Author keywords

Antiviral therapy; HIV; Indinavir; Liposomes; Pharmacokinetics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDINAVIR; LIPID; NANOPARTICLE;

ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; LYMPHOID TISSUE; PRIORITY JOURNAL; SIMULATION; STANDARD; TISSUE DISTRIBUTION; VIRUS INHIBITION; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; DRUG DELIVERY SYSTEMS; HALF-LIFE; HUMANS; INDINAVIR; INJECTIONS, SUBCUTANEOUS; LIPIDS; LYMPHOID TISSUE; MODELS, STATISTICAL; VIRUS REPLICATION;

EID: 33746862611     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9026-1     Document Type: Article

References (15)

1. D. Finzi and R. F. Siliciano. Viral dynamics in HIV-1 infection. Cell 93:665-671 (1998).
2. A. T. Haase. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu. Rev. Immunol. 17:625-656 (1999).
3. W. Cavert, D. W. Notermans, K. Staskus, S. W. Wietgrefe, M. Zupancic, K. Gebhard, K. Henry, Z. Q. Zhang, R. Mills, H. McDade, C. M. Schuwirth, J. Goudsmit, S. A. Danner, and A. T. Haase. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276:960-964 (1997).
4. G. Pantaleo, C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358 (1993).
5. F. Mammano, V. Trouplin, V. Zennou, and F. Clavel. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531 (2000).
6. J. Martinez-Picado, M. P. DePasquale, N. Kartsonis, G. J. Hanna, J. Wong, D. Finzi, E. Rosenberg, H. F. Gunthard, L. Sutton, A. Savara, C. J. Petropoulos, N. Hellmann, B. D. Walker, D. D. Richman, R. Siliciano, and R. T. D'Aquila. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. USA 97:10948-10953 (2000).
7. L. Kinman, S. J. Brodie, C. C. Tsai, T. Bui, K. Larsen, A. Schmidt, D. Anderson, W. R. Morton, S. L. Hu, and R. J. Ho. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J. Acquir. Immune Defic. Syndr. 34:387-397 (2003).
8. T. Lian and R. J. Ho. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90:667-680 (2001).
9. C. Oussoren, J. Zuidema, D. J. Crommelin, and G. Storm. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta. 1328:261-272 (1997).
10. M. A. Boyd, R. E. Aarnoutse, K. Ruxrungtham, M. Stek Jr., R. P. van Heeswijk, J. M. Lange, D. A. Cooper, P. Phanuphak, and D. M. Burger. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J. Acquir. Immune Defic. Syndr. 34:134-139 (2003).
11. B. Clotet, L. Menéndez-Arias, L. Ruiz, C. Tural, A. Vandamme, D. Burger, J. Schapiro, C. A. Boucher, R. D'Aquila, and D. Richman. Guide to management of HIV resistance and pharmacokinetics of drug therapy 94-96 (2000).
12. Yoffey and Courtice. Lymphatics, lymph and lymphoid tissue, 2nd edn. London, 26-27 (1956).
13. Merck & Co., Inc. Crixivan® Prescribing Information, (2004).
14. B. D. M. C. Khoo S. Pharmacology. In G. G. J. Boucher C. A. (ed.), Practical Guidelines in Antiviral Therapy, Elsevier, 2002.
15. C. Solas, A. Lafeuillade, P. Halfon, S. Chadapaud, G. Hittinger, and B. Lacarelle. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:238-243 (2003).